ABSTRACT
The future of therapy for neurodegenerative diseases (NDs) relies on new strategies targeting multiple pharmacological pathways. Our research led to obtaining the compound AR71 [(E)-3-(3,4,5-trimethoxyphenyl)-1-(4-(3-(piperidin-1-yl)propoxy)phenyl)prop-2-en-1-one], which has high affinity for human H3R (Ki = 24 nM) and selectivity towards histamine H1 and H4 receptors (Ki > 2500 nM), and showed anti-inflammatory activity in a model of lipopolysaccharide-induced inflammation in BV-2 cells. The presented tests confirmed its antagonist/inverse agonist activity profile and good metabolic stability while docking studies showed the binding mode to histamine H1, H3, and H4 receptors. In in vitro tests, cytotoxicity was evaluated at three cell lines (neuroblastoma, astrocytes, and human peripheral blood mononuclear cells), and a neuroprotective effect was observed in rotenone-induced toxicity. In vivo experiments in a mouse neuropathic pain model demonstrated the highest analgesic effects of AR71 at the dose of 20 mg/kg body weight. Additionally, AR71 showed antiproliferative activity in higher concentrations. These findings suggest the need for further evaluation of AR71's therapeutic potential in treating ND and CNS cancer using animal experimental models.
Subject(s)
Analgesics , Anti-Inflammatory Agents , Receptors, Histamine H3 , Animals , Humans , Mice , Receptors, Histamine H3/metabolism , Analgesics/pharmacology , Anti-Inflammatory Agents/pharmacology , Ligands , Molecular Docking Simulation , Male , Neuralgia/drug therapy , Neuralgia/metabolism , Neuralgia/chemically induced , Neuroprotective Agents/pharmacology , Neuroprotective Agents/therapeutic use , Lipopolysaccharides , Cell Line, TumorABSTRACT
BACKGROUND: Numerous studies highlight the critical role that neural histamine plays in feeding behavior, which is controlled by central histamine H3 and H1 receptors. This is the fundamental motivation for the increased interest in creating histamine H3 receptor antagonists as anti-obesity medications. On the other hand, multiple other neurotransmitter systems have been identified as pharmacotherapeutic targets for obesity, including sigma-2 receptor systems. Interestingly, in our previous studies in the rat excessive eating model, we demonstrated a significant reduction in the development of obesity using dual histamine H3/sigma-2 receptor ligands. Moreover, we showed that compound KSK-94 (structural analog of Abbott's A-331440) reduced the number of calories consumed, and thus acted as an anorectic compound. Therefore, in this study, we extended the previous research and studied the influence of KSK-94 on adipose tissue collected from animals from our previous experiment. METHODS: Visceral adipose tissue was collected from four groups of rats (standard diet + vehicle, palatable diet + vehicle, palatable diet + KSK-94, and palatable diet + bupropion/naltrexone) and subjected to biochemical, histopathological, and immunohistochemical studies. RESULTS: The obtained results clearly indicate that compound KSK-94 prevented the hypertrophy and inflammation of visceral adipose tissue, normalized the levels of leptin, resistin and saved the total reduction capacity of adipose tissue, being more effective than bupropion/naltrexon in these aspects. Moreover, KSK-94 may induce browning of visceral white adipose tissue. CONCLUSION: Our study suggests that dual compounds with a receptor profile like KSK-94, i.e., targeting histamine H3 receptor and, to a lesser extent, sigma-2 receptor, could be attractive therapeutic options for patients at risk of developing obesity or with obesity and some metabolic disorders. However, more studies are required to determine its safety profile and the exact mechanism of action of KSK-94.
ABSTRACT
This study examines the properties of a novel series of 4-oxypiperidines designed and synthesized as histamine H3R antagonists/inverse agonists based on the structural modification of two lead compounds, viz., ADS003 and ADS009. The products are intended to maintain a high affinity for H3R while simultaneously inhibiting AChE or/and BuChE enzymes. Selected compounds were subjected to hH3R radioligand displacement and gpH3R functional assays. Some of the compounds showed nanomolar affinity. The most promising compound in the naphthalene series was ADS031, which contained a benzyl moiety at position 1 of the piperidine ring and displayed 12.5 nM affinity at the hH3R and the highest inhibitory activity against AChE (IC50 = 1.537 µM). Eight compounds showed over 60% eqBuChE inhibition and hence were qualified for the determination of the IC50 value at eqBuChE; their values ranged from 0.559 to 2.655 µM. Therapy based on a multitarget-directed ligand combining H3R antagonism with additional AChE/BuChE inhibitory properties might improve cognitive functions in multifactorial Alzheimer's disease.
Subject(s)
Cholinesterases , Receptors, Histamine H3 , Molecular Structure , Ligands , Histamine , Cholinesterase Inhibitors/pharmacology , Cholinesterase Inhibitors/chemistry , Ethers , Drug Inverse Agonism , Receptors, Histamine H3/chemistry , Receptors, Histamine , Structure-Activity RelationshipABSTRACT
Floating treatment wetlands (FTWs) are a sustainable solution to treat polluted water, but their role in chromium (Cr(III)) removal under neutral pH conditions remains poorly understood. This study evaluated the potential of FTWs planted with two perennial emergent macrophytes, Phragmites australis and Iris pseudacorus, to remove Cr(III) and nutrients (N and PO4-P) from water containing 7.5 mg/L TN, 1.8 mg/L PO4-P, and Cr(III) (500, 1000, and 2000 µg/L). Within 1 h of exposure, up to 96-99% of Cr was removed from the solution, indicating rapid precipitation. After 50 days, Phragmites bound 9-19% of added Cr, while Iris bound 5-22%. Both species accumulated Cr primarily in the roots (BCF > 1). Biomass production and growth development were inhibited in Cr treatments, but microscopic examination of plant roots revealed no histological changes at 500 and 1000 µg/L Cr, suggesting high resistance of the tested species. At 2000 µg/L Cr, both species exhibited disruptions in the arrangement of vessel elements in the stele and increased aerenchyma spaces in Phragmites. At the end of the experiment, 70-86% of TN and 54-90% of PO4-P were removed.